Endocrinology
News from the FDA/CDC
FDA approves weekly contraceptive patch Twirla
The levonorgestrel and ethinyl estradiol contraceptive is contraindicated in obese women.
Latest News
Radioactive iodine can be first-line for hyperthyroidism, says UK
“Recommending the use of radioactive iodine as first-line treatment for adults with Graves’ disease is a change to current practice.”
Conference Coverage
Noninjectable modes of insulin delivery coming of age
From the Journals
Zoledronate promotes postdenosumab bone retention
Osteoporosis patients given a single infusion of zoledronate after denosumab retained more than half of bone mineral density gains.
News
Teprotumumab gets FDA go-ahead for thyroid eye disease
It is the first drug to be approved for treatment of the debilitating, autoimmune condition.
Conference Coverage
Testosterone gel increases LV mass in older men
PHILADELPHIA – The clinical implications of this hormonal therapy–induced jump in left ventricular mass remain unclear.
Conference Coverage
Treatment of heart failure with preserved ejection fraction is a work in progress
Although the disorder has a lower mortality than heart failure with reduced ejection fraction, it places a significant burden on health care...
Guidelines
New guideline for testosterone treatment in men with ‘low T’
The American College of Physicians has released new clinical guidelines providing practical recommendations for testosterone therapy in adult men...
From the Journals
Anorexia linked to low bone density, osteoporosis
Lower body mass index topped both disease subtype and duration of illness as a predictor of low BMD and probable osteoporosis.
News
Farxiga granted Priority Review for treatment of adults with HFrEF
The Food and Drug Administration is reviewing dapagliflozin for reducing the risk of cardiovascular death or worsening of heart failure in adults...
News
FDA panel okays teprotumumab for thyroid eye disease
Until now, the disease that has not really been treatable, with current treatment aimed at relief of symptoms.